Publications

Commentary: revised susceptibility breakpoints: fear, loathing and good science. by Dudley MN, Ambrose PG and Jones RN published in Pediatr. Infect. Dis. J. 2013; 32 (9): 970-971

Background and rationale for revised Clinical Laboratory Standards Institute (CLSI) interpretive criteria (breakpoints) for Enterobacteriaceae and Pseudomonas aeruginosa: I. Cephalosporins and Aztreonam. by Dudley MN, Ambrose PG, Bhavnani SM, Craig WA, Ferraro MJ and Jones RN published in Clin. Infect. Dis. 2013; 56 (9): 1301-1309

Treatment of methicillin-susceptible Staphylococcus aureus osteoarticular and prosthetic joint infections: Using the oxacillin minimum inhibitory concentration to guide appropriate ceftriaxone use. by Nguyen HM and Jones RN published in Clin. Infect. Dis. 2013; 57 (1): 161-162

Antimicrobial activity of the novel polymyxin derivative NAB739 tested against Gram-negative pathogens. by Vaara M, Sader HS, Rhomberg PR, Jones RN and Vaara T published in J. Antimicrob. Chemother. 2013; 68 (3): 636-639

Relationship between ceftolozane/tazobactam exposure and drug-resistance amplification in a hollow-fiber infection model. by VanScoy B, Mendes RE, Castanheira M, McCauley J, Bhavnani SM, Forrest A, Jones RN, Okusanya OO, Friedrich L, Steenbergen J and Ambrose PG published in Antimicrob. Agents Chemother. 2013; 57 (9): 4134-4138

Update on the prevalence and genetic characterization of NDM-1-producing Enterobacteriaceae in Indian hospitals during 2010. by Castanheira M, Deshpande LM, Farrell SE, Shetye S, Shah N and Jones RN published in Diagn. Microbiol. Infect. Dis. 2013; 75 (2): 210-213

Polymyxins: Wisdom doesn’t always come with age. by Kassamali Z, Rotschafer JC, Jones RN, Prince RA and Danziger LH published in Clin. Infect. Dis. 2013; 57 (6): 877-883

Activity of MK-3118, a new oral glucan synthase inhibitor tested against Candida spp. by two international methods (CLSI and EUCAST). by Pfaller MA, Messer SA, Motyl MR, Jones RN and Castanheira M published in J. Antimicrob. Chemother. 2013; 68 (4): 858-863

Klebsiella pneumoniae carbapenemase-producing Enterobacteriaceae testing susceptible to cefepime by reference methods. by Picao RC, Jones RN, Mendes RE and Castanheira M published in J. Clin. Microbiol. 2013; 51 (7): 2388-2390

Determination of disk diffusion and MIC quality control guidelines for GSK2251052: A novel boron antibacterial. by Ross JE, Scangarella-Oman NE and Jones RN published in Diagn. Microbiol. Infect. Dis. 2013; 75 (4): 437-439

Rifaximin in the treatment of irritable bowel syndrome: is there a high risk for development of antimicrobial resistance? by Farrell DJ published in J. Clin. Gastroenterol. 2013; 47 (3): 205-211

Interim susceptibility testing for ceftaroline, a new MRSA-active cephalosporin: Selecting potent surrogate ß-lactam markers to predict ceftaroline activity against clinically-indicated species. by Jones RN, Flamm RK, Sader HS and Stilwell MG published in Diagn. Microbiol. Infect. Dis. 2013; 75 (1): 89-93

Dissemination of a pSCFS3-like cfr-carrying plasmid in Staphylococcus aureus and Staphylococcus epidermidis clinical isolates recovered from hospitals in Ohio. by Mendes RE, Deshpande LM, Bonilla HF, Schwarz S, Huband MD, Jones RN and Quinn JP published in Antimicrob. Agents Chemother. 2013; 57 (7): 2923-2928

Use of a surfactant (polysorbate 80) to improve MIC susceptibility testing results for polymyxin B and colistin. by Sader HS, Rhomberg PR, Flamm RK and Jones RN. published in Diagn. Microbiol. Infect. Dis. 2012; 74 (4): 412-414

Oritavancin activity against vancomycin-susceptible and vancomycin-resistant enterococci with molecularly characterized glycopeptide resistance genes recovered from bacteremic patients, 2009-2010. by Mendes RE, Woosley LN, Farrell DJ, Sader HS and Jones RN published in Antimicrob. Agents Chemother. 2012; 56 (3): 1639-1642

Activity of JNJ-Q2, a novel fluoroquinolone, tested against Neisseria gonorrhoeae, including ciprofloxacin-resistant strains. by Biedenbach DJ, Turner LL, Jones RN and Farrell DJ published in Diagn. Microbiol. Infect. Dis. 2012; 74 (2): 204-206

Telavancin activity tested against a contemporary collection of Gram-positive pathogens from USA hospitals (2007-2009). by Mendes RE, Sader HS, Farrell DJ and Jones RN published in Diagn. Microbiol. Infect. Dis. 2012; 72 (1): 113-117

Transferable plasmid-mediated resistance to linezolid due to cfr in a human clinical isolate of Enterococcus faecalis by Diaz L, Kiratisin P, Mendes R, Panesso D, Singh KV and Arias CA published in Antimicrob. Agents Chemother. 2012; 56 (7): 3917-3922

Pharmacodynamics of beta-lactamase inhibition by NXL104 in combination with ceftaroline, examining organisms with multiple types of beta-lactamases. by Louie A, Castanheira M, Liu W, Grasso C, Jones RN, Williams G, Critchley I, Thye D, Brown D, Vanscoy B, Kulawy R and Drusano GL published in Antimicrob. Agents Chemother. 2012; 56 (1): 258-270

Ceftaroline applications for therapy in the United States by Corey GR and Jones RN published in Clin. Infect. Dis. 2012; 55 (Suppl 3): S171-S172

Synergistic activity of ceftobiprole and vancomycin in a rat model of infective endocarditis caused by methicillin-resistant and glycopeptide-intermediate Staphylococcus aureus. by Fernandez J, Abbanat D, Shang W, He W, Amsler K, Hastings J, Queenan AM, Melton JL, Barron AM, Flamm RK and Lynch AS published in Antimicrob. Agents Chemother. 2012; 56 (3): 1476-1484

Activity of ceftaroline-avibactam tested against gram-negative organism populations, including strains expressing one or more beta-lactamases and methicillin-resistant Staphylococcus aureus carrying various SCCmec types. by Castanheira M, Sader HS, Farrell DJ, Mendes RE and Jones RN published in Antimicrob. Agents Chemother. 2012; 56 (9): 4779-4785

Activities of E1210 and comparator agents tested by CLSI and EUCAST broth microdilution methods against Fusarium and Scedosporium species identified using molecular methods. by Castanheira M, Duncanson FP, Diekema DJ, Guarro J, Jones RN and Pfaller MA published in Antimicrob. Agents Chemother. 2012; 56 (1): 352-357

Worldwide appraisal and update (2010) of telavancin activity tested against a collection of Gram-positive clinical pathogens from five continents. by Mendes RE, Sader HS, Farrell DJ and Jones RN published in Antimicrob. Agents Chemother. 2012; 56 (7): 3999-4004

Antimicrobial activity of the investigational pleuromutilin compound BC-3781 tested against gram-positive organisms commonly associated with acute bacterial skin and skin structure infections. by Sader HS, Biedenbach DJ, Paukner S, Ivezic-Schoenfeld Z, Jones RN published in Antimicrob. Agents Chemother. 2012; 56 (3): 1619-1623

Characterization of methicillin-resistant Staphylococcus aureus displaying increased MICs of ceftaroline. by Mendes RE, Tsakris A, Sader HS, Jones RN, Biek D, McGhee P, Appelbaum PC and Kosowska-Shick K published in J. Antimicrob. Chemother. 2012; 67 (6): 1321-1324

Comparison of Escherichia coli ST131 pulsotypes, by epidemiologic traits, 1967-2009. by Johnson JR, Nicolas-Chanoine MH, DebRoy C, Castanheira M, Robicsek A, Hansen G, Weissman S, Urban C, Platell J, Trott D, Zhanel G, Clabots C, Johnston BD and Kuskowski MA published in Emerg. Infect. Dis. 2012; 18 (4): 598-607

The changing epidemiology of healthcare-associated candidemia over three decades. by Diekema D, Arbefeville S, Boyken L, Kroeger J and Pfaller M published in Diagn. Microbio. Infect. Dis. 2012; 73 (1): 45-48

Activity of ceftobiprole against Streptococcus pneumoniae isolates exhibiting high-level resistance to ceftriaxone. by Davies TA, Flamm RK and Lynch AS published in Int. J. Antimicrob. Agents. 2012; 39 (6): 534-538

Activity of JNJ-Q2, a new fluoroquinolone, tested against contemporary pathogens isolated from patients with community-acquired bacterial pneumonia. by Biedenbach DJ, Farrell DJ, Flamm RK, Liverman LC, McIntyre G and Jones RN published in Int. J. Antimicrob. Agents. 2012; 39 (4): 321-325

Unmet needs and prospects for oritavancin in the management of vancomycin-resistant enterococcal infections. by Arias CA, Mendes RE, Stilwell MG, Jones RN and Murray BE published in Clin. Infect. Dis. 2012; 54 (Suppl 3): S233-S238

Antimicrobial activity of the novel pleuromutilin antibiotic BC-3781 against organisms responsible for community-acquired respiratory tract infections (CARTIs). by Sader HS, Paukner S, Ivezic-Schoenfeld Z, Biedenbach DJ, Schmitz FJ and Jones RN published in J. Antimicrob. Chemother. 2012; 67 (5): 1170-1175

Antimicrobial activity of daptomycin in comparison to glycopeptides and other antimicrobials when tested against numerous species of coagulase-negative Staphylococcus. by Sader HS and Jones RN published in Diagn. Microbiol. Infect. Dis. 2012; 73 (2): 212-214

Wild-type MIC distributions and epidemiological cutoff values for amphotericin B, flucytosine, and itraconazole and Candida spp. as determined by CLSI broth microdilution. by Pfaller MA, Espinel-Ingroff A, Castanheira M, Cuenca-Estrella M, Diekema DJ, Fothergill A, Faller J, Ghannoum M, Jones RN, Lockhart SR, Ostrosky-Zeichner L and Pelaez T published in J. Clin. Microbiol. 2012; 50 (6): 2040-2046

Disk diffusion and MIC quality control ranges for BC-3205 and BC-3781, two novel pleuromutilin antibiotics. by Ross JE, Sader HS, Ivezic-Schoenfeld Z, Paukner S and Jones RN published in J. Clin. Microbiol. 2012; 50 (10): 3361-3364

Challenges in assessing microbial susceptibility and predicting clinical response to newer-generation fluoroquinolones. by Segreti J, Jones RN and Bertino JS published in J. Ocul. Pharmacol. Ther. 2012; 28 (1): 3-11

Analytical and clinical validation of novel real-time reverse transcriptase-polymerase chain reaction assays for the clinical detection of swine-origin H1N1 influenza viruses. by Duncan C, Guthrie JL, Tijet N, Elgngihy N, Turenne C, Seah C, Lau R, McTaggart L, Mallo G, Perusini S, Rebbapragada A, Melano R, Low DE, Farrell D and Guyard C published in Diagn. Microbiol. Infect. Dis. 2011; 69 (2):167-171

Longitudinal survey of carbapenem resistance and resistance mechanisms in Enterobacteriaceae and non-fermenters from the USA in 2007-09. by Davies TA, Marie Queenan A, Morrow BJ, Shang W, Amsler K, He W, Lynch AS, Pillar C and Flamm RK published in J. Antimicrob. Chemother. 2011; 66 (10): 2298-2307

Wild-type MIC distributions and epidemiologic cutoff values for fluconazole, posaconazole, and voriconazole when testing Cryptococcus neoformans as determined by the CLSI broth microdilution method. by Pfaller MA, Castanheira M, Diekema DJ, Messer SA and Jones RN published in Diagn. Microbiol. Infect. Dis. 2011; 71 (3): 252-259

Plasmid-borne vga(A)-encoding gene in methicillin-resistant Staphylococcus aureus ST398 recovered from swine and a swine farmer in the United States. by Mendes RE, Smith TC, Deshpande L, Diekema DL, Sader HS and Jones RN published in Diagn. Microbiol. Infect. Dis.2011; 71 (2): 177-180

Definitions and epidemiology of Candida species not susceptible to echinocandins by Pfaller MA, Diekema DJ, Castanheira M and Jones RN published in Curr. Fungal Infect. Rep. 2011; 5: 120-127

Antimicrobial activty of CXA-101, a novel cephalosporin tested in combination with tazobactam against Enterobacteriaceae, Pseudomonas aeruginosa, and Bacteroides fragilis strains having various resistance phenotypes. by Sader HS, Rhomberg PR, Farrell DJ, Jones RN published in Antimicrob. Agents Chemother. 2011; 55 (5): 2390-2394

Wild-type MIC distributions and epidemiological cutoff values for posaconazole and voriconazole and Candida spp. as determined by 24-hour CLSI broth microdilution. by Pfaller MA, Boyken L, Hollis RJ, Kroeger J, Messer SA, Tendolkar S and Diekema DJ published in J. Clin. Microbiol. 2011; 49 (2): 630-637

Tigecycline activity tested against multidrug-resistant Enterobacteriaceae and Acinetobacter spp. isolated in US medical centers. by Sader HS, Farrell DJ and Jones RN published in Diagn. Microbiol. Infect. Dis. 2011; 69 (2): 223-227

Triazole and echinocandin wild-type MIC distributions with epidemiological cutoff values for six uncommon species of Candida. by Pfaller MA, Castanheira M, Diekema DJ, Messer SA and Jones RN published in J. Clin. Microbiol. 2011; 49 (11): 3800-3804

Investigation of the potential for mutational resistsance to XF-73, retapamulin, mupirocin, fusidic acid, daptomycin, and vancomycin in methicillin-resistant Staphylococcus aureus isolates during a 55-passage study by Farrell DJ, Robbins M Rhys-Williams and Love WG published in Antimicrob. Agents Chemother. 2011; 55 (3): 1177-1181

Efficacy of a new fluoroquinolone, JNJ-Q2, in murine models of Staphylococcus aureus and Streptococcus pneumoniae skin, respiratory, and systemic infections. by Fernandez J, Hilliard JJ, Morrow BJ, Melton JL, Flamm RK, Barron AM and Lynch AS published in Antimicrob. Agents Chemother. 2011; 55 (12): 5522-5528

Comment on: Role of changes in the L3 loop of the active site in the evolution of enzymatic activity of VIM-type metallo-beta-lactamases. by Castanheira M, Deshpande LM, Mendes RE, Rodriguez-Noriega E, Jones RN, Morfin-Otero, R published in J. Antimicrob. Chemother. 2011; 66 (3): 684-685

Determination of disk diffusion and MIC quality control ranges for GSK1322322, a novel peptide deformylase inhibitor. by Ross JE, Scangarella-Oman NE, Miller LA, Sader HS and Jones RN published in J. Clin. Microbiol. 2011; 49 (11): 3928-3930

Determination of disk diffusion and MIC quality control guidelines for JNJ-Q2, a novel quinolone. by Ross JE, Liverman LC and Jones RN published in J. Clin. Microbiol. 2011; 49 (8): 3009-3011